Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Hepatitis Delta a Major Global Problem: Screening, Diagnosis, and Treatment in 2022 – Physician Discussion #1

In this podcast, CCO’s expert faculty discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.
Heiner Wedemeyer, MD
Released: March 30, 2022

In this episode, Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.

Information on this Educational Activity

Faculty

Heiner Wedemeyer, MD

Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany

Heiner Wedemeyer, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Altimmune, Biotest, Bristol-Myers Squibb, BTG, Dicerna, Enanta, Gilead, Janssen, Merck/MSD, MYR, Roche, and Vir; has received funds for research support from AbbVie, Biotest, Gilead, Merck/MSD, and Roche; and has served as a clinical trials investigator for AbbVie, Altimmune, Bristol-Myers Squibb, Gilead, Janssen, Merck/MSD, MYR, Novartis, and Vir.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
AbbVie
Gilead Sciences, Inc.

Related Content

Prof Heiner Wedemeyer discusses emerging treatment options for HDV and therapeutic questions that still need answers, from Clinical Care Options (CCO)

Heiner Wedemeyer, MD Released: March 23, 2022

Dr. Heiner Wedemeyer and Dr. Cihan Yurdaydin: rational use of new and emerging treatment options for HDV, from Clinical Care Options (CCO)

Heiner Wedemeyer, MD person default Cihan Yurdaydin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 16, 2022 Expired: March 15, 2023

Dr. Heiner Wedemeyer and Dr. Cihan Yurdaydin: steps to take in patients coinfected with HBV and HDV, from Clinical Care Options (CCO)

Heiner Wedemeyer, MD person default Cihan Yurdaydin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 10, 2022 Expired: March 9, 2023

Stefan Zeuzem, MD, reviews the place in therapy of new and investigational treatments for HDV, from Clinical Care Options (CCO)

Stefan Zeuzem, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: March 9, 2022 Expired: March 8, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings